What are the future ramifications to Pharma Marketers.

F.D.A. Deal Allows Amarin to Promote Drug for Off-Label Use

 

Read here: 

http://www.nytimes.com/2016/03/09/business/fda-deal-allows-amarin-to-promote-drug-for-off-label-use.html?_r=0

 

Considering the FDA denotes this is a special case it still opens pandora's box of off label marketing of ethical pharmaceuticals as long as they are within truthful statements of the appicable clinical study. It will be interesting to see the developments from this action.

 

Please reload

Featured Posts

I'm busy working on my blog posts. Watch this space!

Please reload

Recent Posts

December 28, 2017

Please reload

Archive
Please reload

Search By Tags

I'm busy working on my blog posts. Watch this space!

Please reload

Follow Us
  • Facebook Basic Square
  • Twitter Basic Square
  • Google+ Basic Square

© o2 Marketing Communications, Inc., 2019

PO Box 193, Brielle, NJ 08730

info@o2mktcomm.com / P- 732 -221-4850